Ph.D., Founder, AgeX Therapeutics, Inc.
Michael D. West, Ph.D. founded AgeX (NYSE US: AGE) in 2017 to develop therapeutics related to human aging. He was previously CEO/Co-CEO of regenerative medicine company BioTime Inc., for ten years. Prior to that he was Chairman and CEO of Advanced Cell Technology, which, as Ocata Therapeutics, acquired by Astellas Pharma in 2016 for $379 Million. In 1990 Dr. West founded Geron Corp., where he created the research consortium that led to the first isolation of human embryonic stem cells. Dr. West is the author of numerous papers in peer-reviewed scientific journals as well as “The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Aging” (Doubleday, 2003). He has appeared as a guest on NBC’s “Meet the Press” and has testified before the U.S. Congress on the potential benefits of regenerative medicine.
Emerging Therapeutics Showcase: AgeX Therapeutics, Inc.
AgeX Therapeutics developments novel therapeutics targeting human aging, developing medicines designed to address large unmet medical needs.
Aging & Regenerative Medicine: An Emerging Synthesis
An introduction to product development at AgeX, including data on the potential use of its proprietary induced Tissue Regeneration (iTR) technology in cancer diagnosis and therapy as well as in inducing the destruction of aged cells (a process known as “senolysis”).